2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N2115
    Araloside A 7518-22-1 99.86%
    Araloside A (Chikusetsusaponin IV), triterpenoid saponins, is an orally active component of Aralia elata. Araloside A shows low-renin-inhibitory activity with an IC50 of 77.4 μM. Araloside A can inhibit cell proliferation and induce apoptosis. Araloside A suppresses inflammatory cytokines IL-1β and IL-6 production. Araloside A can be used for the researches of cancer, inflammation and cardiovascular disease, such as renal cell carcinoma and rheumatoid arthritis.
    Araloside A
  • HY-N2129
    N-Nornuciferine 4846-19-9 99.94%
    N-Nornuciferine is an orally active, blood-brain barrier-permeable CYP2D6 inhibitor, with an IC50 of 3.76 μM and a Ki of 2.34 μM against human CYP2D6. N-Nornuciferine also acts as a BChE inhibitor, showing an IC50 of 5.6 μM in mice. N-Nornuciferine can be used in the research of neurological-related diseases.
    N-Nornuciferine
  • HY-N2509
    Iristectorigenin B 86849-77-6 99.48%
    Iristectorigenin B (Iristectrigenin B) is a liver X receptor (LXR) modulator. Iristectrigenin B stimulates the transcriptional activity of both LXR-α and LXR-β.
    Iristectorigenin B
  • HY-N2531
    Notoginsenoside Fc 88122-52-5 ≥99.0%
    Notoginsenoside Fc, a protopanaxadiol- (PPD-) type saponin isolated from the leaves of Panax notoginseng, effectively counteracts platelet aggregation. Notoginsenoside Fc can accelerate reendothelialization following vascular injury in diabetic rats by promoting autophagy.
    Notoginsenoside Fc
  • HY-N2638
    Ilexsaponin A 108524-93-2 99.53%
    Ilexsaponin A, isolated from the root of Ilex pubescens, attenuates ischemia-reperfusion-induced myocardial injury through anti-apoptotic pathway. Ilexsaponin A can reduce myocardial infarct size, lower the serum levels of LDH, AST and CK-MB, increase cellular viability and inhibit apoptosis in hypoxia/reoxygenation cardiomyocytes.
    Ilexsaponin A
  • HY-N3181
    Nodosin 10391-09-0 98.61%
    Nodosin is an orally active diterpenoid compound that can be isolated from Isodon serra. Nodosin can inhibit the proliferation and induce cell cycle arrest and apoptosis of tumor cells. Nodosin can also inhibit oxidative stress, inflammatory responses, and ferroptosis. Nodosin has anti-inflammatory and anti-tumor activities.
    Nodosin
  • HY-N3225
    Myricanol 33606-81-4 98.93%
    Myricanol is a diarylheptanoid and a Nampt activator. Myricanol exerts anti-inflammatory effects and alleviates glucocorticoid-induced muscle atrophy by increasing Sirtuin 1 (SIRT1) and PRDX5 activities while regulating inflammatory factors. Myricanol exhibits growth inhibition and induces apoptosis in human lung adenocarcinoma A549 cells. Myricanol promotes autophagy-mediated clearance of microtubule-associated protein tau to exert neuroprotective effects. Myricanol protects cardiovascular function by inhibiting PDGFRβ and NF-κB signaling pathways. Myricanol activates mitochondrial transcription factor A (TFAM) expression to exert anti-renal fibrosis effects. Myricanol improves insulin resistance through AMPK activation.
    Myricanol
  • HY-N4090
    Vicenin 3 59914-91-9 99.90%
    Vicenin 3 is an angiotensin-converting enzyme (ACE) inhibitor (IC50 = 46.91 μM) that can be isolated from the aerial parts of Desmodium styracifolium. Vicenin 3 ameliorates IL-1β-induced extracellular matrix degradation in SW1353 chondrocytes by regulating the MAPK pathway. Vicenin 3 can be used for the study of osteoarthritis (OA) and hypertension.
    Vicenin 3
  • HY-N5049
    Alcesefoliside 124151-38-8
    Alcesefoliside is a flavonoid isolated from Nitraria sibirica Pall, with antioxidant activity.
    Alcesefoliside
  • HY-N5073
    Vitexin-4''-O-glucoside 178468-00-3 99.86%
    Vitexin-4''-O-glucoside (4''-O-Glucosylvitexin) is an orally active natural flavonoid component with multiple pharmacological effects including antioxidation, anti-inflammation, cytoprotection and anti-apoptosis. Vitexin-4''-O-glucoside regulates the MAPK signaling pathway by downregulating the phosphorylation levels of JNK and p38, thereby blocking endoplasmic reticulum stress responses. Vitexin-4''-O-glucoside alleviates oxidative stress by reducing MDA content and upregulating the activities of SOD and CAT, attenuates inflammation by downregulating the expressions of inflammatory factors TNF-α, IL-1β and IL-6, and also reduces LDH release and inhibits caspase-3 activation. Vitexin-4''-O-glucoside effectively improves drug-induced acute liver injury and exerts significant protective effects against myocardial hypoxia/reoxygenation injury. Vitexin-4''-O-glucoside can be used in studies on acute liver injury, cardiovascular diseases and myocardial hypoxia-reoxygenation injury.
    Vitexin-4''-O-glucoside
  • HY-N6745
    Citreoviridin 25425-12-1 98.39%
    Citreoviridin, a toxin from Penicillium citreoviride NRRL 2579, inhibits brain synaptosomal Na+/K+-ATPase whereas in microsomes, both Na+/K+-ATPase and Mg2+-ATPase activities are significantly stimulated in a dose-dependent manner. Citreoviridin inhibits cell proliferation and enhances apoptosis of human umbilical vein endothelial cells.
    Citreoviridin
  • HY-N7607
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside 143016-74-4 99.87%
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside is a flavonoid glycoside with antioxidant activity and free radical scavenging activity. Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside can scavenge free radicals such as ABTS+ and can be used in the study of antioxidant-related diseases (such as cardiovascular diseases and neurodegenerative diseases).
    Quercetin-3-O-D-glucosyl]-(1-2)-L-rhamnoside
  • HY-P1112
    Sarafotoxin S6a 126738-34-9 98.59%
    Sarafotoxin S6a, a sarafotoxin analogue, is a endothelin receptor agonist and has an ETA/ETB selectivity profile similar to that of Endothelin-3 (HY-P0204). Sarafotoxin S6a elicits the pig coronary artery with an EC50 value of 7.5 nM.
    Sarafotoxin S6a
  • HY-P1271
    Catestatin 142211-96-9 98.17%
    Catestatin is a 21-amino acid residue, cationic and hydrophobic peptide. Catestatin is an endogenous peptide that regulates cardiac function and blood pressure. Catestatin is a non-competitive nicotinic antagonist acting through nicotinic acetylcholine receptors (nAChRs) to inhibit catecholamine release.
    Catestatin
  • HY-P1469
    Bradykinin (1-6) 23815-88-5 99.60%
    Bradykinin (1-6) is an amino-truncated Bradykinin peptide. Bradykinin (1-6) is a stable metabolite of Bradykinin, cleaved by carboxypeptidase Y (CPY).
    Bradykinin (1-6)
  • HY-P1525
    Melanin Concentrating Hormone, salmon 87218-84-6 99.09%
    Melanin Concentrating Hormone, salmon is a 19-amino-acid neuropeptide initially identified in the pituitary gland of teleost fish, which regulates food intake, energy balance, sleep state, and the cardiovascular system. Melanin-concentrating hormone is a ligand for an orphan G protein-coupled receptor (SLC-1/GPR24) and MCHR2.
    Melanin Concentrating Hormone, salmon
  • HY-P1656
    (D-Pro7)-Angiotensin I/II (1-7) 586962-44-9 99.95%
    (D-Pro7)-Angiotensin I/II (1-7) is a potent Mas receptor inhibitor with a Ki of 0.001 μM for rat receptors. (D-Pro7)-Angiotensin I/II (1-7) competitively blocks the binding of Angiotensin-(1-7) to the Mas receptor and attenuates the vasodilatory effect of rat aortas under physiological and hypertensive conditions. (D-Pro7)-Angiotensin I/II (1-7) can be used for studies on the function of the renin-angiotensin system and the pathological mechanisms of hypertension.
    (D-Pro7)-Angiotensin I/II (1-7)
  • HY-P1741
    Fibrinogen-Binding Peptide 137235-80-4 99.83%
    Fibrinogen-Binding Peptide (designed by anticomplementarity hypothesis) is a presumptive peptide mimic of the vitronectin binding site on the fibrinogen receptor. Fibrinogen-Binding Peptide binds fibrinogen and inhibits both the adhesion of platelets to fibrinogen and platelet aggregation, and also inhibits the adhesion of platelets to vitronectin.
    Fibrinogen-Binding Peptide
  • HY-P1770
    Adrenomedullin (16-31), human 318480-38-5 99.96%
    Adrenomedullin (16-31), human is amino acid residues 16-31 fragment of human adrenomedullin (hADM). Adrenomedullin has appreciable affinity for the CGRP1 receptor. Adrenomedullin (16-31), human possesses pressor activity in the systemic vascular bed of the rat, but not the cat.
    Adrenomedullin (16-31), human
  • HY-P1921
    YRGDS Fibronectin Fragment 134282-68-1 98.46%
    YRGDS Fibronectin Fragment is a fibronectin fragment, an adhesion peptide that displays strong binding affinity to thrombin-stimulated platelets.
    YRGDS Fibronectin Fragment
Cat. No. Product Name / Synonyms Application Reactivity